相关实验视频
Updated: Jul 5, 2026

08:18
A Model of Chronic Nutrient Infusion in the Rat
Published on: August 14, 2013
全球葡萄糖类-2受体激活与英国生物银行肥胖风险增加有关
Peter A Gerlach1, Sarina Gadgaard2, Jakob S Madsen3
1Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Nørre Alle 14, 2200, Copenhagen N, Denmark; Department of Drug Design and Pharmacology, Center for Pharmaceutical Data Science Education, University of Copenhagen, Jagtvej 160, 2100 Ø, Copenhagen, Denmark.
Metabolism: clinical and experimental
|January 10, 2026
概括
类似葡萄糖-2受体 (GLP-2R) 的激活会增加肥胖风险,特别是常见的D470N变种. 然而,功能丧失的变体与减小肥胖风险和体脂有关.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 人类遗传学 人类遗传学
背景情况:
- 葡萄糖类-2受体 (GLP-2R) 是肥胖和2型糖尿病 (T2D) 的潜在治疗标.
- GLP-2R激活对人类代谢特征的确切影响和潜在机制尚未完全理解.
研究的目的:
- 从药理上描述GLP-2R误解变异,并评估它们与人类代谢特征的关联.
- 阐明GLP-2R变异的信号机制及其对肥胖和T2D风险的影响.
主要方法:
- 使用cAMP生产和β-arrestin-2招募试验,对30种GLP-2R误解变体进行了体外表征.
- 在大约500,000名英国生物库参与者的遗传关联分析中,将变异与代谢表型联系起来.
- 预测的功能丧失 (pLoF) 变体的计算识别.
主要成果:
- 鉴定了GLP-2R变体,其受体信号发生变化,包括增加 (例如D470N) 和减少活性.
- 常见的D470N变体 (32%的频率) 显示cAMP产量增加,与降低β-arrestin招募和内部化有关.
- D470N与肥胖,T2D,高BMI,体脂,HbA1c和血压的风险增加有关;LoF变种与肥胖风险和体脂的降低有关.
结论:
- 全球GLP-2R激活与肥胖风险增加有关.
- 这项研究强调了GLP-2R在代谢疾病中的作用,并为开发向治疗提供了信息,考虑到GLP-2R调节的潜在不良影响.
相关概念视频
GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

